These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 34392398)

  • 1. The legacy effect in diabetes: are there long-term benefits?
    Folz R; Laiteerapong N
    Diabetologia; 2021 Oct; 64(10):2131-2137. PubMed ID: 34392398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of intensive versus conventional glucose control on microvascular and macrovascular complications in type 1 and 2 diabetes mellitus.
    Mattila TK; de Boer A
    Drugs; 2010 Dec; 70(17):2229-45. PubMed ID: 21080740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic memory: Evolving concepts.
    Misra A; Bloomgarden Z
    J Diabetes; 2018 Mar; 10(3):186-187. PubMed ID: 29091343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Issues surrounding tight glycemic control in people with type 2 diabetes mellitus.
    Cerveny JD; Leder RD; Weart CW
    Ann Pharmacother; 1998 Sep; 32(9):896-905. PubMed ID: 9762378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycemic Control and Excess Cardiovascular Mortality in Type 1 Diabetes.
    Teleb M; Popp Switzer M; Elhanafi S; Elfar A; San Juan ZT
    Curr Cardiol Rep; 2016 Mar; 18(3):29. PubMed ID: 26886228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.
    Hemmingsen B; Lund SS; Gluud C; Vaag A; Almdal TP; Hemmingsen C; Wetterslev J
    Cochrane Database Syst Rev; 2013 Nov; (11):CD008143. PubMed ID: 24214280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensive insulin regimens: evidence for benefit.
    Bretzel RG
    Int J Obes Relat Metab Disord; 2004 Sep; 28 Suppl 2():S8-13. PubMed ID: 15306832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormonal versus non-hormonal contraceptives in women with diabetes mellitus type 1 and 2.
    Visser J; Snel M; Van Vliet HA
    Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD003990. PubMed ID: 23543528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature.
    Nalysnyk L; Hernandez-Medina M; Krishnarajah G
    Diabetes Obes Metab; 2010 Apr; 12(4):288-98. PubMed ID: 20380649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucocentric risk factors for macrovascular complications in diabetes: Glucose 'legacy' and 'variability'-what we see, know and try to comprehend.
    Monnier L; Colette C; Schlienger JL; Bauduceau B; R Owens D
    Diabetes Metab; 2019 Oct; 45(5):401-408. PubMed ID: 30685425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Legacy Effect of Intensive Blood Glucose Control on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Very High Risk or Secondary Prevention of Cardiovascular Disease: A Meta-analysis of Randomized Controlled Trials.
    Zhang X; Liu Y; Zhang F; Li J; Tong N
    Clin Ther; 2018 May; 40(5):776-788.e3. PubMed ID: 29656857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Legacy benefits of blood glucose, blood pressure and lipid control in individuals with diabetes and cardiovascular disease: Time to overcome multifactorial therapeutic inertia?
    Khunti K; Kosiborod M; Ray KK
    Diabetes Obes Metab; 2018 Jun; 20(6):1337-1341. PubMed ID: 29405543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic review on urine albumin testing for early detection of diabetic complications.
    Newman DJ; Mattock MB; Dawnay AB; Kerry S; McGuire A; Yaqoob M; Hitman GA; Hawke C
    Health Technol Assess; 2005 Aug; 9(30):iii-vi, xiii-163. PubMed ID: 16095545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormonal versus non-hormonal contraceptives in women with diabetes mellitus type 1 and 2.
    Visser J; Snel M; Van Vliet HA
    Cochrane Database Syst Rev; 2006 Oct; (4):CD003990. PubMed ID: 17054193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.
    Hemmingsen B; Lund SS; Gluud C; Vaag A; Almdal T; Hemmingsen C; Wetterslev J
    Cochrane Database Syst Rev; 2011 Jun; (6):CD008143. PubMed ID: 21678374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term mortality and retinopathy in type 1 diabetes.
    Grauslund J
    Acta Ophthalmol; 2010 May; 88 Thesis1():1-14. PubMed ID: 20500731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort.
    Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group
    Diabetes Care; 1999 Jan; 22(1):99-111. PubMed ID: 10333910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.